Methylation sequencing features a lower limit of detection (LoD) and a signal independent from clonal hematopoiesis (CHIP) variants/biological noise.¹
Methylation-based detection identifies and quantifies tumor signals in early- and late-stage cancers with as low as 0.001% circulating tumor fraction (TF).¹
Methylation-based tumor fraction has superior sensitivity, enabling identification of tumor signal in 15%-50% more cancer patients.¹
Methylation sequencing dramatically improves sensitivity in cancer monitoring vs genomic signals alone.¹
Home GuardantINFINITY™ FDA Approved Guardant360® CDx Guardant Reveal™ Guardant Infinity Platform™